Lieberman Jay R, Roth Kevin M, Elsissy Peter, Dorey Frederick J, Kobashigawa Jon A
The Musculoskeletal Institute and the Department of Orthopaedic Surgery, University of Connecticut Health Center, Farmington, CT 06030-5456, USA.
J Arthroplasty. 2008 Jan;23(1):90-6. doi: 10.1016/j.arth.2007.01.006.
Patients who are treated with steroids for immunosuppression after solid organ transplant are at risk for development of osteonecrosis. The purpose of this study was to determine the prevalence of symptomatic osteonecrosis of the hip and knee in patients who were treated with corticosteroids after cardiac transplantation and to determine if there was a relationship between steroid dose and the development of osteonecrosis. We retrospectively evaluated 204 patients who underwent cardiac transplantation and noted that only 6 (3%) of 204 patients developed symptomatic osteonecrosis of the hip or knee. The osteonecrosis was diagnosed an average of 38.5 months (range, 21-52 months) after transplantation. There was no association noted between steroid dose and the development of symptomatic osteonecrosis. The low prevalence of osteonecrosis supports the hypothesis that the development of osteonecrosis in these patients is an idiosyncratic response to steroids, perhaps related to an underlying hypercoagulable state or hypofibrinolysis.
实体器官移植后接受类固醇免疫抑制治疗的患者有发生骨坏死的风险。本研究的目的是确定心脏移植后接受皮质类固醇治疗的患者髋部和膝部有症状性骨坏死的患病率,并确定类固醇剂量与骨坏死的发生之间是否存在关联。我们回顾性评估了204例接受心脏移植的患者,发现204例患者中只有6例(3%)发生了髋部或膝部有症状性骨坏死。骨坏死在移植后平均38.5个月(范围21 - 52个月)被诊断出来。未发现类固醇剂量与有症状性骨坏死的发生之间存在关联。骨坏死的低患病率支持了这样一种假设,即这些患者骨坏死的发生是对类固醇的一种特异反应,可能与潜在的高凝状态或纤维蛋白溶解功能减退有关。